FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Hatteras Venture Advisors IV SBIC.					2. Issuer Name and Ticker or Trading Symbol Clearside Biomedical, Inc. [CLSD]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner								
LLC				3. Date of Earliest Transaction (Month/Day/Year) 01/17/2017									er (give titl	е		r (specify				
(Last)	(Fir	,	Middle))												Ma	y be part	ofa	13(d) Gro	oup
280 S. MANGUM STREET, SUITE 350			4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)									
(Street)	M NO	2	7701	1]		filed by M		eporting Penan One R	
(City)	(Sta	ate) (Z	Zip)																	
		Tabl	eI-	Non-Deriv	ative	Se	cu	rities	Ac	quired	, Di	sposed of	f, or B	enef	cial	ly Own	ed			
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye				Year) E	Execution D		on Date	Ė	3. Transaction Code (Instr. 8)			s Acquired (A) of (D) (Instr. 3, 4			5. Amou Securiti Benefic Owned Followi	es ially	Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
								Code	v	Amount	(A) or (D)	Pric	e	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)				
Common Stock 01/1			01/17/20	17					S		9,806	D	\$8.	.92(1)	2,08	0,364		I	See Footnote ⁽²⁾	
Common Stock 01/18/2			01/18/20	.7					S		12,258	D	\$8.	.64(3)	2,06	8,106		I	See Footnote ⁽²⁾	
Common Stock 01/19/201			17	7				S		7,592	D	D \$8.22		2,06	2,060,514		I	See Footnote ⁽²⁾		
		Та	ble	II - Derivat (e.g., pı								osed of, o				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Exec if an	Deemed sution Date, y nth/Day/Year)	4. Transa Code (I 8)			5. Nun of Deriva Securi Acquii (A) or Dispos of (D) (Instr. and 5)	tive ties red sed 3, 4	Expirat (Month	ion [7. Title Amoun Securit Underl Derivat Securit 3 and 4	it of ies ying ive y (Inst	0 E S (I	B. Price of Derivative Security Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	e s lly	10. Ownershi Form: Direct (D) or Indirec (I) (Instr. 4)	Beneficial Ownership
					Code		v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	Amou or Numb of Share	er					
		Reporting Person		BIC, LLC	<u>}</u>															
(Last) 280 S. M		(First) TREET, SUITE		Middle)		-														
(Street)	M	NC	2	27701																
(City)		(State)	(Zip)		_														

Last) 280 S. MANGU	(First) JM STREET, SUIT	(Middle)
Street) OURHAM	NC	27701
City)	(State)	(Zip)
Name and Addi	ress of Reporting Pers	on [*]
	(First) AS VENTURES JM STREET, SUIT	(Middle)
Street) OURHAM	NC	27701
City)	(State)	(Zip)
	ress of Reporting Pers	
	(First) AS VENTURES JM STREET, SUIT	(Middle)
Street) OURHAM	NC	27701
City)	(State)	(Zip)
Name and Add	ress of Reporting Pers	on [*]
	(First) AS VENTURES JM STREET, SUIT	(Middle)
Street) OURHAM	NC	27701
City)	(State)	(Zip)
	ress of Reporting Pers	on [*]
<u>Reed Doug</u>		(Middle)
Last) C/O HATTER A	(First) AS VENTURES JM STREET, SUIT	E 350
Last) C/O HATTER A	AS VENTURES	E 350 27701

1. Name and Addi	I. Name and Address of Reporting Person* Thorp Clay								
(Last)	(First)	(Middle)							
C/O HATTERAS VENTURES									
280 S. MANGUM STREET, SUITE 350									
(Street)									
DURHAM	NC	27701							
,									
(City)	(State)	(Zip)							

Explanation of Responses:

- 1. This transaction was executed in multiple trades at prices ranging from \$8.68 to \$9.22. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
- 2. The reportable securities are owned directly by Hatteras Venture Partners IV SBIC, LP ("HVP IV"). Hatteras Venture Advisors IV SBIC, LLC is the general partner of HVP IV (the "GP"). The securities directly held by HVP IV are indirectly held by the individual managing members of GP (each, a "GP Managing Member" and collectively, the "GP Managing Members"). The GP Managing Members are John Crumpler, Clay Thorp, Ken Lee, Douglas Reed and Robert Ingram. The GP Managing Members may share voting and dispositive power over the securities directly held by HVP IV. Each GP Managing Member disclaims beneficial ownership of these securities and this report is not an admission that any GP Managing Member is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.
- 3. This transaction was executed in multiple trades at prices ranging from \$8.42 to \$8.79. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
- 4. This transaction was executed in multiple trades at prices ranging from \$8.01 to \$8.65. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

/s/ Thomas A. Allen, attorneyin-fact for Hatteras Venture 01/19/2017 Advisors IV SBIC, LLC /s/ Thomas A. Allen, attorneyin-fact for Hatteras Venture Advisors IV SBIC, LLC, the 01/19/2017 general partner of Hatteras Venture Partners IV SBIC, LP /s/ Thomas A. Allen, attorney-01/19/2017 in-fact for John C. Crumpler /s/ Thomas A. Allen, attorney-01/19/2017 in-fact for Robert A. Ingram /s/ Thomas A. Allen, attorney-01/19/2017 in-fact for Kenneth B. Lee /s/ Thomas A. Allen, attorney-01/19/2017 in-fact for Douglas Reed /s/ Thomas A. Allen, attorney-01/19/2017 in-fact for Clay B. Thorp ** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

Know all by these presents that the undersigned hereby constitutes and appoints each of Thomas A. Allen and Andrew J. Gibbons, and each of them acting alone, signing singly, the undersigned's true and lawful attorney-in-fact to:

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director, and/or 10% or more stockholder of Clearside Biomedical , Inc. (the "Company"), Forms ID, 3, 4 and 5 and Schedules 13D or 13G (and any amendments thereto) under Section 13(d) and 16(a) of the Securities Exchange Act of 1934, as amended (the "1934 Act") in accordance with the 1934 Act, and the rules promulgated thereunder;
- (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form or Schedule (and any amendments thereto) and to file timely such Form or Schedule with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
- (3) take any other action of any type whatsoever in connection with the foregoing which in the opinion of such attorney-infact may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-infact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorneyin-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 13(d) or 16(a) of the 1934 Act.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file such Forms or Schedules with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to each of the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 18th day of January 2017.

HATTERAS VENTURE ADVISORS IV SBIC, LLC

By: /s/ Clay B. Thorp Name: Clay B. Thorp Title: Manager

HATTERAS VENTURE PARTNERS IV SBIC, LP

By: Hatteras Venture Advisors IV SBIC, LLC, its general partner

By: /s/ Clay B. Thorp

Name: Clay B. Thorp Title: Manager

/s/ John C. Crumpler John C. Crumpler

/s/ Robert A. Ingram Robert A. Ingram

/s/ Kenneth B. Lee Kenneth B. Lee

/s/ Douglas Reed Douglas Reed

/s/ Clay B. Thorp Clay B. Thorp